PDCD1 and non-small cell lung carcinoma: Over the last decade, there has been a substantial increase in the number of approved therapies for the treatment of advanced NSCLC stemming from the discovery of immune checkpoints such as programmed cell death-1 (PD-1) and CTLA-4 (4–7) as well as an ever-increasing array of driver mutations with matching targeted therapies (8).